
Marinus Pharmaceuticals Inc is a biotechnology business based in the US. Marinus Pharmaceuticals shares (MRNS) are listed on the NASDAQ and all prices are listed in US Dollars. Marinus Pharmaceuticals employs 113 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Marinus Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MRNS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Marinus Pharmaceuticals stock price (NASDAQ: MRNS)
Use our graph to track the performance of MRNS stocks over time.Marinus Pharmaceuticals shares at a glance
Latest market close | $4.84 |
---|---|
52-week range | $3.97 - $19.40 |
50-day moving average | $5.75 |
200-day moving average | $9.55 |
Wall St. target price | $30.11 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.48 |
Buy Marinus Pharmaceuticals shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Marinus Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Marinus Pharmaceuticals price performance over time
Historical closes compared with the close of $4.84 from 2022-06-30
1 week (2022-06-24) | -3.01% |
---|---|
1 month (2022-05-28) | N/A |
3 months (2022-04-01) | -48.46% |
6 months (2021-12-31) | -59.26% |
1 year (2021-07-01) | -74.12% |
---|---|
2 years (2020-07-01) | 81.27% |
3 years (2019-07-01) | 12.82% |
5 years (2017-06-30) | 253.28% |
Marinus Pharmaceuticals financials
Revenue TTM | $27.7 million |
---|---|
Gross profit TTM | $-54,568,000 |
Return on assets TTM | -38.4% |
Return on equity TTM | -116.86% |
Profit margin | 0% |
Book value | $0.97 |
Market capitalisation | $189.1 million |
TTM: trailing 12 months
Marinus Pharmaceuticals share dividends
We're not expecting Marinus Pharmaceuticals to pay a dividend over the next 12 months.
Have Marinus Pharmaceuticals's shares ever split?
Marinus Pharmaceuticals's shares were split on a 1:4 basis on 23 September 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marinus Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Marinus Pharmaceuticals shares which in turn could have impacted Marinus Pharmaceuticals's share price.
Marinus Pharmaceuticals share price volatility
Over the last 12 months, Marinus Pharmaceuticals's shares have ranged in value from as little as $3.97 up to $19.397. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marinus Pharmaceuticals's is 1.5027. This would suggest that Marinus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Marinus Pharmaceuticals overview
Marinus Pharmaceuticals, Inc. , a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.
Marinus Pharmaceuticals in the news
What Type Of Shareholders Make Up Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Registry?
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Frequently asked questions
What percentage of Marinus Pharmaceuticals is owned by insiders or institutions?Currently 0.519% of Marinus Pharmaceuticals shares are held by insiders and 83.033% by institutions. How many people work for Marinus Pharmaceuticals?
Latest data suggests 113 work at Marinus Pharmaceuticals. When does the fiscal year end for Marinus Pharmaceuticals?
Marinus Pharmaceuticals's fiscal year ends in December. Where is Marinus Pharmaceuticals based?
Marinus Pharmaceuticals's address is: 5 Radnor Corporate Center, Radnor, PA, United States, 19087 What is Marinus Pharmaceuticals's ISIN number?
Marinus Pharmaceuticals's international securities identification number is: US56854Q2003 What is Marinus Pharmaceuticals's CUSIP number?
Marinus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 56854Q101
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert